In a recent issue of Journal of Clinical Oncology, Berry et al. 1 report a meta-analysis using individual data from the randomized trials of high doses of chemotherapy (HDC) with autologous hematopoietic stem-cell transplantation (AHSCT) in high-risk primary breast cancer (BC) patients. Of 6210 patients who participated in the 15 trials, HDC achieved a significant 13% reduction in the risk of recurrence (Po0.001), but this did not translate into a significant OS benefit (P ¼ 0.13). Since the presentation of Berry's results, the scientific community 2 has considered the argument for HDC chemotherapy with AHSCT in BC to be over owing to a lack of definite OS benefit.
We think that this conclusion may be questionable and that there are still reasons to believe that this treatment has a role in BC management. First, OS has been traditionally used as the major end point of the effectiveness of a new treatment modality. In recent years, this concept has been challenged. 3 Instead, relapse-free survival (RFS) is often considered the best way of evaluating a treatment, including adjuvant therapy, 4 because it takes into account the risk of death associated with the therapy, and is not influenced by old and newer treatments given after relapse. The point is whether even a small improvement in RFS justifies giving all patients more aggressive and toxic treatment. Second, early studies of HDC showed unacceptably high mortality, and these distort the meta-analysis. In fact, outcome analysis, which excludes treatment-related mortality, suggests an advantage of HDC, in terms of OS. It should also be borne in mind that HDC with PBSCs support today is a safe procedure 5 with a mortality rate and quality-adjusted survival parameters 6 similar to conventional therapies. Third, not all patients in those trials had biomarker information, such as HER2 and hormone-receptor status, and the meta-analysis was not able to address biomarker-based subgroups of patients who would benefit from HDC. Nevertheless, when looking at subgroup analyses, OS data in the HER2-negative population appear quite encouraging. Although only 27% of patients had the HER2 status available, survival was assessed in 1260 HER2 À patients (379 triple-negative). The positive effect of HDC in the whole HER2 À population, not discussed by Berry et al.,
1 even more marked in the triple-negative disease, is biologically plausible and sustained by clinical evidence. [7] [8] [9] Fourth, the heterogeneity of the trials in terms of chemotherapy regimens used may affect the result of the meta-analysis.
In summary, what the scientific community has considered to be completely negative data do not truly represent a negative outcome for HDC with AHSCT in high-risk primary BC, and we believe that, also in view of the present absence of novel targeted drugs available in the adjuvant setting of HER2 À disease, the data provided by Berry et al. 1 should reopen and do not close the discussion on HDC, which should be re-evaluated in clinical studies focusing on triple-negative disease. Starting from these considerations, the new studies should define the standard regimen used and investigate different approaches for combining HDC with AHSCT. With the introduction of mobilized PBSCs collection techniques, collection of doses of stem cells that far exceed the thresholds required for engraftment can be readily achieved. This permits an approach consisting of multiple cycles of HDC followed by the infusion of PBSCs after each cycle in an attempt to increase the intensity of anticancer therapy beyond that achievable with a standard autologous transplantation. Evidence indicates that this approach increases the long-term disease-free and OS rate over that achieved with standard transplantation.
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